{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:57:04Z","timestamp":1781161024862,"version":"3.54.1"},"reference-count":32,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The addition of CD-38 monoclonal antibody daratumumab (DARA) to front-line therapy for newly diagnosed multiple myeloma (NDMM) has improved outcomes. The real-world (RW) adoption of treatments remains inconsistent. We aimed to evaluate the adoption of DARA regimens in the treatment of NDMM. Methods: We conducted a retrospective study at a multi-site academic\u2013community healthcare system from August 2020\u2013September 2023. Patients (n = 414) were \u226518 years with NDMM upon initiating front-line therapy. Results: The median age was 69; most were male (60.6%, n = 251), white (69.1%, n = 286), and non-Hispanic (89.6%, n = 371). At diagnosis, 52.2% (n = 216) had R-ISS stage II, and the performance status was preserved, with 69.3% (n = 287) having ECOG 0\u20131. The adoption of DARA-based induction was incomplete (53.9%, n = 223) and was higher at the academic myeloma center than the community sites (63.9% vs. 47.7%; p = 0.001). At three months after treatment initiation, patients receiving DARA-based induction achieved deeper responses than those treated without DARA. The distribution of IMWG responses favored the DARA group, with a higher proportion attaining VGPR or better (65.0% [n = 145] vs. 51.3% [n = 98]). Conclusions: DARA-based regimens for NDMM were underutilized and notably less common at community sites. Coordinated implementation strategies at the provider and community levels may narrow adoption gaps and translate trial-proven benefits into routine practice.<\/jats:p>","DOI":"10.3390\/cancers18121899","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:50:58Z","timestamp":1781157058000},"page":"1899","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic\u2013Community Network"],"prefix":"10.3390","volume":"18","author":[{"given":"Poy","family":"Theprungsirikul","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA"},{"name":"Dana Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4082-6251","authenticated-orcid":false,"given":"Amer","family":"Al-Musa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8383-1867","authenticated-orcid":false,"given":"Noffar","family":"Bar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina L.","family":"Browning","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-077X","authenticated-orcid":false,"given":"Natalia","family":"Neparidze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone induction and consolidation followed by lenalidomide maintenance in multiple myeloma","volume":"32","author":"Roussel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed myeloma (SWOG S0777)","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"van de Donk, N.W.C.J., Usmani, S.Z., Richardson, P.G., Plesner, T., Lokhorst, H.M., Mateos, M.V., Lonial, S., Dimopoulos, M.A., Orlowski, R.Z., and Leleu, X. (2018). CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02134"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS)","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone in relapsed or refractory multiple myeloma (CASTOR)","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA)","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma (GRIFFIN)","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Final analysis of daratumumab plus RVd in transplant-eligible newly diagnosed multiple myeloma","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Long-term follow-up of the CASSIOPEIA randomized controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2023-174044","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high-risk newly diagnosed myeloma patients","volume":"142","author":"Touzeau","year":"2023","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Overall survival results from the MAIA randomized phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma (CEPHEUS)","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to RVd induction in newly diagnosed multiple myeloma (GMMG-HD7)","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Final analysis of isatuximab-RVd induction therapy in transplant-eligible newly diagnosed multiple myeloma (GMMG-HD7)","volume":"43","author":"Mai","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","article-title":"Quadruplet regimens for patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis","volume":"8","author":"Ebraheem","year":"2024","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e180798","DOI":"10.1001\/jamaoncol.2018.0798","article-title":"Speed of adoption of immune checkpoint inhibitors and comparison of patient ages in clinical practice versus pivotal trials","volume":"4","author":"Fessele","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2200246","DOI":"10.1200\/PO.22.00246","article-title":"Impact of clinical practice gaps on the implementation of personalized medicine in advanced non\u2013small-cell lung cancer","volume":"6","author":"Sadik","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Paulson, R.S., Gautam, S., Medhekar, R., Mahmud, S., Mirsalehi, A., Ensley, L., Shelley, B., Brisbin, L., Lisi, M., and Khare, V. (2026). Front-line treatment approaches in multiple myeloma: Real-world data from a community-based oncology network. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1736892"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Suzuki, K., Fujimori, Y., Sakai, C., Tsuchiya, H., Koroki, Y., Yamada, T., Nakazato, T., Iida, S., Takezako, N., and Nagura, E. (2025). Real-world treatment outcomes of different sequencing options with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible multiple myeloma in Japan. Cancers, 17.","DOI":"10.3390\/cancers17091389"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"925.e1","DOI":"10.1016\/j.jtct.2024.05.011","article-title":"TACTUM: Trends in access to cellular therapies in multiple myeloma","volume":"30","author":"Atallah","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/10600280211058754","article-title":"Daratumumab for the treatment of multiple myeloma: Clinical applicability and operational considerations","volume":"56","author":"Arnall","year":"2022","journal-title":"Ann. Pharmacother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1899\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:04:17Z","timestamp":1781157857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121899"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121899","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}